24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Copaxone
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:23
Intel shares fall back to April levels after losing over half their value in five weeks
21:50
Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast
21:37
Ground Up Ventures appoints Navot Volk as General Partner
21:22
After years of delays, IDF prepares to deploy Elbit’s new Ro'em artillery systems
More stories
Buzz
Most popular
Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Israeli digital health company TailorMed acquired in $250 million deal
4
Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company
5
Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast
More news
Copaxone
5 stories about Copaxone
Teva's Blockbuster Drug Takes Another Generic Blow
26.10.17
|
Lilach Baumer
Mylan and European Partner Synthon won U.K. patent case related to Teva's Copaxone
Teva’s Stock Drops After Approval of Copaxone Competitors
08.10.17
|
Lilach Baumer
A day after Mylan announced FDA approval for its generic versions of Copaxone, drug companies Synthon and Alvogen announce European approval for their 40 mg/ml generic versions of Teva's blockbuster drug
Teva Loses Copaxone Market Exclusivity
04.10.17
|
Lilach Baumer
Rival Mylan received FDA approval for its generic versions of Copaxone, Teva’s flagship drug
New CEO to Break Teva’s Copaxone Habit
11.09.17
|
Sophie Shulman, Dror Reich
Troubled drugmaker says new CEO must work to quickly regain its financial credibility
With Bloated Debt, Teva Looks to Sell Assets
10.08.17
|
Eli Shimony and Gil Kalian
The generic drugmaker said it is looking to sell Medis, an Iceland-based company it bought in 2016
Previous Articles